Letters to the EditorOctreotide for protein-losing enteropathy with intestinal lymphangiectasia
References (5)
- et al.
Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue
Gastroenterology
(1992) - et al.
Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis
Eur J Pharmacol
(1994)
There are more references available in the full text version of this article.
Cited by (67)
Complicated primary intestinal lymphangiectasia (Waldmann's disease) in a child successfully treated with octreotide: A case report from a low-resource setting
2021, Annals of Medicine and SurgeryCitation Excerpt :For Klingenberg and all, the mechanism of action is an inhibition of the action of the endocrine and exocrine peptidergic glands of the gastrointestinal tract [27]. The efficacy of treatment with Octreotide has been demonstrated in cases described in medicine literature [23,26,28], some of which have not been found to be more effective than the regimen [29]. During the patient's follow-up, the evolution after almost two years of the introduction of octreotide compared to the diet alone showed a very good evolution of clinical signs.
Nutrition and metabolism in the critically ill child with cardiac disease
2018, Critical Heart Disease in Infants and ChildrenProtein-losing enteropathy during highly active antiretroviral therapy in a patient with AIDS-related disseminated Mycobacterial avium complex infection
2009, Journal of Infection and ChemotherapyVideocapsule endoscopy as a useful tool to diagnose primary intestinal lymphangiectasia
2007, Revue de Medecine InterneNutrition and Metabolism in the Critically Ill Child with Cardiac Disease
2006, Critical Heart Disease in Infants and ChildrenGastrointestinal Manifestations of Primary Immunodeficiency
2006, Pediatric Gastrointestinal and Liver Disease
Copyright © 1995 Published by Elsevier Ltd.